Polymorphisms of Death Pathway Genes FAS and FASL in Esophageal Squamous-Cell Carcinoma
Open Access
- 6 July 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 96 (13) , 1030-1036
- https://doi.org/10.1093/jnci/djh187
Abstract
Background: The FAS receptor–ligand system is a key regulator of apoptotic cell death, and loss of FAS expression and gain of FAS ligand (FASL) expression play important roles in the development and progression of cancer. Single-nucleotide polymorphisms in the promoter region of the FAS (G or A at position –1377 [FAS –1377G/A] and A or G at position –670 [FAS –670A/G]) and FASL (T or C at position –844 [FASL –844T/C]) genes alter the transcriptional activity of these genes. We examined the association between these polymorphisms and risk of the development and metastasis of esophageal squamous-cell carcinoma. Methods: Genotypes of 588 case patients with esophageal squamous-cell carcinoma and 648 control subjects were determined by polymerase chain reaction–based restriction fragment length polymorphism. Associations with the risk of esophageal squamous-cell carcinoma were estimated by logistic regression. All statistical tests were two-sided. Results: We observed a statistically significantly increased risk of esophageal squamous-cell carcinoma associated with the FAS –1377AA (odds ratio [OR] = 1.79, 95% confidence interval [CI] = 1.29 to 2.48; P <.001) or FAS –670GG (OR = 1.72, 95% CI = 1.26 to 2.34; P <.001) genotype, which are in strong linkage disequilibrium compared with the FAS –1377GA or GG or the FAS –670AG or AA genotype, respectively. An increased risk of esophageal squamous-cell carcinoma was also associated with the FASL –844CC genotype (OR = 2.06, 95% CI = 1.64 to 2.59; P <.001) compared with the FASL –844CT or TT genotype. Gene–gene interactions of FAS and FASL polymorphisms increased the risk of esophageal squamous-cell carcinoma in a multiplicative manner (OR for the presence of both FAS –1377AA and FASL –844CC genotypes = 4.55, 95% CI = 2.75 to 7.48; P = .001, test for homogeneity). Statistically significant interactions were found between these polymorphisms in FAS and FASL and tobacco smoking. None of the polymorphisms was associated with risk of differentiation or metastasis of esophageal squamous-cell carcinoma at diagnosis. Conclusion: Genetic polymorphisms in the death pathway genes FAS and FASL appear to be associated with an increased risk of developing esophageal squamous-cell carcinoma.Keywords
This publication has 28 references indexed in Scilit:
- Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesisInternational Journal of Cancer, 2002
- Evaluation of a Apo-1/Fas promoter polymorphism in Korean stroke patientsExperimental & Molecular Medicine, 2002
- Mitochondrial oxidative stress and CD95 ligand: A dual mechanism for hepatocyte apoptosis in chronic alcoholismHepatology, 2002
- Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenariansCell Death & Differentiation, 2002
- Gene–environment interaction and aetiology of cancer: what does it mean and how can we measure it?Carcinogenesis: Integrative Cancer Research, 2002
- Ethanol-Induced Apoptosis in Mouse LiverThe American Journal of Pathology, 2001
- Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligandCell, 1994
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993
- The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosisCell, 1991
- Monoclonal Antibody-Mediated Tumor Regression by Induction of ApoptosisScience, 1989